Diterpenoid from Croton tonkinensis as a Potential Radiation Sensitizer in Oral Squamous Cell Carcinoma: An In Vitro Study
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252111839 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Hui-Ming Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Surgery, Department of Surgery, E-Da Cancer Hospital, I-Shou University, Kaohsiung 824005, Taiwan. Hauptthemen laut MEDLINE: Croton, Mouth Neoplasms, Radiation-Sensitizing Agents, Cell Survival. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: E-Da Hospital.
Abstract (Originalsprache)
Radiotherapy combined with a radiosensitizer represents an important treatment for head and neck squamous cell carcinoma (HNSCC). Only a few chemotherapy agents are currently approved as radiosensitizers for targeted therapy. Oral squamous cell carcinoma is one of the deadliest cancers, with approximately ~500,000 new diagnosed cases and 145,000 deaths worldwide per year. The incidence of new cases continues to increase in developing countries. This study aimed to investigate the effect of Croton tonkinensis and Curcuma longa on cell viability in OSCC cells. The HNSCC cell line OML1 and its radiation-resistant clone OML1-R were used. The anticancer effect and the mechanism of action of Croton tonkinensis and Curcuma longa in OSCC cells were analyzed by using cell viability assays, Western blot analysis, and Tranwell migration assays. The results showed that Croton tonkinensis concentration-dependently reduced the viability of OML1 and OML1-R (radioresistant) cells by downregulating the levels of AKT/mTOR mediators, such as p110α, p85, pAKT (ser473), p-mTOR (ser2448), and p-S6 Ribosomal (ser235/236). We found that cotreatment of OML1 and OML1R cells with either zVAD-FMK (apoptosis inhibitor), Ferrostatin-1 (Fer-1, a ferroptosis inhibitor), or chloroquine (CQ, an autophagy inhibitor) markedly reduced cell death. These results demonstrate that Croton tonkinensis exhibits anti-proliferation activity and highlight the therapeutic potential of small-molecule inhibitors against PI3K/mTOR signaling for radiosensitization in HNC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of General Surgery, Department of Surgery, E-Da Cancer Hospital, I-Shou University, Kaohsiung 824005, Taiwan.
- School of Chinese Medicine for Post Baccalaureate, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
- School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.
- Department of Dentistry, E-Da Hospital, I-Shou University, Kaohsiung 824005, Taiwan.
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan.
- Department of Medical Research, E-Da Hospital, Kaohsiung 824, Taiwan.
ORCID-Profile: Ping-Chung Kuo, Po-Jen Chen, Yu-Chieh Su
Förderung
- E-Da Hospital
Zitieren
APA
Lee, H. M., Kuo, P. C., Chen, W. H., Chen, P. J., Lam, S. H., Su, Y. C., & Chen, C. H. (2024). Diterpenoid from Croton tonkinensis as a Potential Radiation Sensitizer in Oral Squamous Cell Carcinoma: An In Vitro Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111839
Vancouver
Lee HM, Kuo PC, Chen WH, Chen PJ, Lam SH, Su YC, et al. Diterpenoid from Croton tonkinensis as a Potential Radiation Sensitizer in Oral Squamous Cell Carcinoma: An In Vitro Study. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111839
BibTeX
@article{Lee2024,
author = {Lee, Hui-Ming and Kuo, Ping-Chung and Chen, Wen-Hui and Chen, Po-Jen and Lam, Sio-Hong and Su, Yu-Chieh and Chen, Chih-Hao},
title = {Diterpenoid from Croton tonkinensis as a Potential Radiation Sensitizer in Oral Squamous Cell Carcinoma: An In Vitro Study},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252111839}
}
EUVIMED